TMEM170B, identified as a transmembrane protein located in the plasma membrane, serves a crucial role in negatively regulating the canonical Wnt signaling pathway. The canonical Wnt pathway is a fundamental signaling cascade that plays a pivotal role in various cellular processes, including embryonic development, tissue homeostasis, and stem cell maintenance. TMEM170B's involvement in this pathway positions it as a key modulator, contributing to the delicate balance required for proper cellular function. The primary function of TMEM170B lies in its ability to negatively regulate the canonical Wnt signaling pathway. This implies that TMEM170B acts as a suppressor, mitigating the activation of downstream events triggered by Wnt signaling. The canonical Wnt pathway typically involves the stabilization of β-catenin, which translocates to the nucleus and regulates gene expression. TMEM170B's negative regulation likely involves interference with this process, perhaps by promoting β-catenin degradation or inhibiting its stabilization, thereby downregulating Wnt-mediated cellular responses. Given its localization in the plasma membrane, TMEM170B is strategically positioned to modulate the reception and transmission of extracellular signals involved in canonical Wnt signaling.
The inhibition of TMEM170B involves a diverse array of mechanisms targeting the canonical Wnt pathway. Some inhibitors directly interact with components of the Wnt pathway, disrupting events like β-catenin stabilization or Wnt ligand secretion. Others act indirectly by modulating parallel signaling pathways, such as the MAPK/ERK or Hedgehog pathways, impacting TMEM170B through cross-talk mechanisms. These diverse mechanisms reflect the complexity of regulatory networks, showcasing how TMEM170B inhibition is intricately intertwined with multiple cellular pathways. The detailed exploration of these inhibitors not only provides insights into TMEM170B's function but also sheds light on the interconnectedness of signaling cascades in cellular regulation. Overall, understanding TMEM170B and its inhibition contributes to the broader comprehension of the intricate molecular networks governing cellular processes.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
XAV939 | 284028-89-3 | sc-296704 sc-296704A sc-296704B | 1 mg 5 mg 50 mg | $36.00 $117.00 $525.00 | 26 | |
Direct inhibitor of TMEM170B by suppressing the canonical Wnt signaling pathway. Blocks tankyrase activity, promoting degradation of Axin1 and inhibiting β-catenin stabilization, thereby negatively regulating TMEM170B. | ||||||
LGK 974 | 1243244-14-5 | sc-489380 sc-489380A | 5 mg 50 mg | $359.00 $1295.00 | 2 | |
Inhibits TMEM170B indirectly by targeting the Wnt pathway. Blocks Porcupine, preventing Wnt ligand secretion, leading to reduced activation of the Wnt pathway and subsequent negative regulation of TMEM170B. | ||||||
IWP-2 | 686770-61-6 | sc-252928 sc-252928A | 5 mg 25 mg | $96.00 $292.00 | 27 | |
Indirect inhibitor influencing TMEM170B by inhibiting Wnt ligand secretion. Blocks Porcupine, disrupting Wnt signaling and promoting negative regulation of TMEM170B through the canonical Wnt pathway. | ||||||
PRI-724 | 1422253-38-0 | sc-507535 | 25 mg | $260.00 | ||
Targets the Wnt/β-catenin pathway, indirectly affecting TMEM170B. Inhibits CBP/β-catenin interaction, disrupting downstream transcriptional events and leading to negative regulation of TMEM170B. | ||||||
NSC 668036 | 144678-63-7 | sc-507412 | 5 mg | $175.00 | ||
Inhibits TMEM170B indirectly by suppressing Wnt signaling. Targets Dishevelled, disrupting its function in Wnt pathway activation, leading to negative regulation of TMEM170B through the canonical Wnt signaling cascade. | ||||||
β-Catenin/Tcf Inhibitor, FH535 | 108409-83-2 | sc-221398 sc-221398A | 10 mg 50 mg | $182.00 $374.00 | 7 | |
Targets TMEM170B indirectly by inhibiting Wnt signaling. Dual inhibitor of PPARγ and β-catenin, disrupting the cross-talk between Wnt and PPARγ pathways, leading to negative regulation of TMEM170B. | ||||||
Encorafenib | 1269440-17-6 | sc-507422 | 1 mg | $115.00 | ||
Targets TMEM170B indirectly by modulating the MAPK/ERK pathway. Inhibits BRAF, disrupting MAPK/ERK signaling, leading to negative regulation of TMEM170B through mechanisms independent of canonical Wnt signaling. | ||||||
ETC-159 | 1638250-96-0 | sc-507415 | 5 mg | $90.00 | ||
Inhibits TMEM170B indirectly by targeting the Hedgehog (Hh) signaling pathway. Blocks Smoothened (SMO), disrupting Hh signaling and promoting negative regulation of TMEM170B through mechanisms parallel to canonical Wnt modulation. | ||||||
GSK-3 Inhibitor IX | 667463-62-9 | sc-202634 sc-202634A sc-202634B | 1 mg 10 mg 50 mg | $58.00 $188.00 $884.00 | 10 | |
Indirect inhibitor influencing TMEM170B through GSK-3β modulation. Inhibits GSK-3β, promoting β-catenin degradation and inhibiting the canonical Wnt pathway, thereby negatively regulating TMEM170B. | ||||||